Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 16 citations · 29 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyImmunotherapyOncology PharmacotherapyCancer ImmunotherapyDosing Of Immuno-oncology AgentsImmunotherapy SafetyMultiple MyelomaCross-study ComparabilityEfficacy Data EvaluationInverse Probability WeightingMultiple Myeloma TherapyMultiple Myeloma TreatmentPropensity ScoringRefractory Multiple MyelomaRelapsed Multiple Myeloma
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)–adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
29
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14